Northwire Canada EditionSaturday, July 11, 2026
Sign inSubscribe
Northwire
⌕
GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0% GLDN 0.055 +0.0% BRON 0.040 +0.0% BTO 5.43 −0.7% ESK 0.365 −2.7% AUMN 0.275 +0.0% GGX 0.040 +0.0% S 0.155 +29.2% NNX 0.035 +0.0% ABX 51.90 −0.6% TTS 2.40 −4.0% FCI 0.400 −9.1% GR 0.075 +0.0% AII 23.38 +12.4% TUNG 1.72 +1.8% LGO 1.01 −2.9% EMM 0.080 +0.0%
M&A / Property Routine +

Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement

Crescita Therapeutics Secures Final Court Approval for ClinActiv Acquisition; Shares Trade Near Offer Price

By The Northwire Desk — AI Analysis May 20, 2026 · 17:07 CTX · 0.76 CRESCITA THERAPEUTICS INC. J
Executive Summary
  • Crescita Therapeutics Inc. has obtained final court approval from the Ontario Superior Court of Justice for its plan of arrangement with ClinActiv Holdings Inc.
  • The transaction is an all-cash acquisition at $0.80 per share, subject to net working capital adjustments with a guaranteed minimum of $0.75 per share.
  • Completion is expected in the second quarter of 2026, leading to the delisting of Crescita's shares from the TSX and cessation as a reporting issuer.
  • This follows shareholder approval on May 14, 2026, where 99.58% voted in favor.
  • The deal was originally announced in March 2026 with a ~74% premium to the five-day VWAP.
Material Impact
  • Certainty of Closing: The final court order removes the last major regulatory hurdle, significantly de-risking the transaction compared to earlier stages (March announcement).
  • Price Efficiency: The stock price has already adjusted to reflect the deal terms, trading at $0.76 against an offer of $0.80. This news confirms the path to closing but does not introduce new valuation upside.
  • Arbitrage Spread: The remaining spread ($0.04) represents the risk-free return until close, assuming no working capital adjustments reduce the price below the minimum guarantee.
  • Delisting Risk: Post-closing, shares will be delisted; this news confirms the timeline for liquidity exit is on track.
  • Classification: As a procedural milestone in a fully priced-in transaction announced months ago, this is Routine - Positive rather than Material - Game Changer, as expectations were already met by previous shareholder and interim court approvals.
CTX · Price
Company Overview
  • Business Model: Crescita operates a diversified healthcare business including commercial skincare products, contract manufacturing services (CMO), and licensing/royalties.
  • Flagship Assets: Bacti Control® brand IP acquired from Laboratoire Provence-Canada Inc., Pliaglis® rights regained via Croma Pharma termination, and manufacturing facility in Ontario.
  • Operational Status: Manufacturing segment revenue surged to $2.4M in Q1 2026 (up from $830k YoY), driving overall growth alongside commercial skincare ($3.05M).
  • Financial Health: Strong cash position of $8.71M as of Q1 2026, with positive Adjusted EBITDA of $238k in the same period.
Read the original news release →

More from CRESCITA THERAPEUTICS INC. J

Jun 03, 2026 · 18:07

Crescita Therapeutics Closes $0.80 All-Cash Acquisition by ClinActiv, Delisting TSX and Cashing Out Shareholders

M&A / Property Jun 01, 2026 · 20:59

Crescita Therapeutics Inc.

M&A / Property May 14, 2026 · 13:48

Crescita shareholders overwhelmingly back ClinActiv buyout, paving the way for a clean exit at the premium offer.

M&A / Property May 11, 2026 · 07:30

Crescita Shares Trade Near Buyout Price as Q1 EBITDA Turnaround Validates Deal Viability

Earnings Apr 22, 2026 · 19:13

Crescita Therapeutics Moves Closer to ClinActiv Takeover at $0.80 Premium

M&A / Property Mar 31, 2026 · 07:30

Crescita Locks $0.80 Buyout as Q4 Earnings Validate Manufacturing Pivot

Earnings